February 26, 2007

Fujirebio Diagnostics Inc and ARUP Laboratories have signed an agreement to offer Mesomark Assay, an in-vitro test for monitoring mesothelioma.

Beginning today, all Mesomark patient samples will be tested by ARUP. The company processes more than 25,000 specimens of blood, body fluid, and tissue biopsies per day for clients located throughout the United States.

Between 1979 and 2001, at least 43,000 people died from the form of cancer linked to asbestos exposure according to the Environmental Working Group. This number could be even higher, since this type of cancer has only been tracked as a cause of death since 1999.

The test kit was developed by Fujirebio to monitor patients confirmed as having mesothelioma, for recurrence in patients following surgery, or for measuring response to therapies.

More information can be found at Fujirebio’s Web site.